The National Cancer Institute (NCI) sees research co-development partners and/or licensees for an automated acoustophoresis device to radio-label and isolate cells.
This technology includes an illuminator and reflector that enables flexible standing wave illumination on an inverted microscope stand, and procedures for using such illumination to improve axial resolution in confocal or instant SIM imaging systems. The axial resolution in conventional fluorescence microscopy is typically limited by diffraction to ~700 nm. This method that improves axial resolution ~7-fold over the diffraction limit, and that can be applied to any fluorescence microscope.
Cancer cells may acquire drug resistance after prolonged chemotherapy. In many cases, cancer cells develop resistance to several drugs with distinct structures and modes of action. This multi-drug resistance phenomenon increases the complexity of cancer treatment.
Bladder cancer is the fifth most common cancer in the United States and one of the costliest cancers to treat. Compared to other cancer types, bladder cancer has been understudied, and there is a need for informative mouse bladder cancer models that resemble the clinical situation and allow for evaluation of chemotherapeutic or immunotherapeutic agents. The orthotopic murine bladder cancer model MB49 resembles non-muscle invasive, nonmetastatic urothelial carcinomas and provides an opportunity to study the anti-tumor effects of immune cell checkpoint inhibitors.
Nonalcoholic fatty liver disease is caused by several factors including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant. TCDD causes lipid accumulation in humans by inducing the Solute Carrier Family 46 Member 3 (SLC46A3) gene expression. To effectively study TCDD-mediated lipid accumulation, research tools such as SLC46A3 knockout cells and animal models are required.
The Centers for Disease Control and Prevention (CDC) and the National Institute for Allergy and Infectious Diseases (NIAID) have been rewarded for their partnership from the 2021 Federal Laboratory Consortium (FLC) awards. The CDC and NIAID had already developed a new approach to sharing samples during a Public Health Emergency of International Concern (PHEIC) during the Zika pandemic, which enabled them to respond quickly and efficiently to access and share samples of SARS-CoV-2 early in the outbreak.
Within hours of the public release of the viral genome sequence, scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) and their collaborators engineered a key protein from SARS-CoV-2, the virus that causes COVID-19, to enable its study as a vaccine candidate and for research applications.
In recognition of pioneering research and development that has brought NIH technology from the theoretical realms of the laboratory to clinical applications.
Awardee
National Heart Lung and Blood Institute
In recognition of pioneering research and development and an unsurpassed commitment to transferring NIH/NIA technology to benefit mankind.
Awardee
National Institute on Aging
Reactive mast cells are the culprit in allergic diseases and have also been implicated in other diseases ranging from autoimmune disorders to cancer to atherosclerosis. These immune sentinel cells normally defend against parasites and bacteria, but sometimes they overreact to harmless intruders, such as pollens or plant oils, releasing granules loaded with inflammation-inciting molecules, such as histamine, as well as various proteases and cytokines that cause allergic and inflammatory reactions.